Gastric Cancer Treatments and Survival Trends in the United States
Gastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. T...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/1/17 |
| _version_ | 1797520748436258816 |
|---|---|
| author | Kelly A. Stahl Elizabeth J. Olecki Matthew E. Dixon June S. Peng Madeline B. Torres Niraj J. Gusani Chan Shen |
| author_facet | Kelly A. Stahl Elizabeth J. Olecki Matthew E. Dixon June S. Peng Madeline B. Torres Niraj J. Gusani Chan Shen |
| author_sort | Kelly A. Stahl |
| collection | DOAJ |
| description | Gastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. The National Cancer Database was used to identify gastric adenocarcinoma patients from 2004–2016. Chi-square tests were used to examine subgroup differences between disease stages: Stage I, II/III and IV. Multivariate analyses identified factors associated with the receipt of guideline concordant care. The Kaplan–Meier method was used to assess three-year overall survival. The final cohort included 108,150 patients: 23,584 Stage I, 40,216 Stage II/III, and 44,350 Stage IV. Stage specific guideline concordant care was received in only 73% of patients with Stage I disease and 51% of patients with Stage II/III disease. Patients who received guideline consistent care had significantly improved survival compared to those who did not. Overall, we found only moderate improvement in guideline adherence and three-year overall survival during the 13-year study time period. This study showed underutilization of stage specific guideline concordant care for stage I and II/III disease. |
| first_indexed | 2024-03-10T08:01:02Z |
| format | Article |
| id | doaj.art-6b50ae6d2b1f430aa59817c974cbf8b4 |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T08:01:02Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-6b50ae6d2b1f430aa59817c974cbf8b42023-11-22T11:27:05ZengMDPI AGCurrent Oncology1198-00521718-77292020-12-0128113815110.3390/curroncol28010017Gastric Cancer Treatments and Survival Trends in the United StatesKelly A. Stahl0Elizabeth J. Olecki1Matthew E. Dixon2June S. Peng3Madeline B. Torres4Niraj J. Gusani5Chan Shen6Department of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17036, USADepartment of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17036, USADepartment of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17036, USADepartment of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17036, USADepartment of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17036, USADepartment of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17036, USADepartment of Surgery, College of Medicine, The Pennsylvania State University, Hershey, PA 17036, USAGastric cancer is the third most common cause of cancer deaths worldwide. Despite evidence-based recommendation for treatment, the current treatment patterns for all stages of gastric cancer remain largely unexplored. This study investigates trends in the treatments and survival of gastric cancer. The National Cancer Database was used to identify gastric adenocarcinoma patients from 2004–2016. Chi-square tests were used to examine subgroup differences between disease stages: Stage I, II/III and IV. Multivariate analyses identified factors associated with the receipt of guideline concordant care. The Kaplan–Meier method was used to assess three-year overall survival. The final cohort included 108,150 patients: 23,584 Stage I, 40,216 Stage II/III, and 44,350 Stage IV. Stage specific guideline concordant care was received in only 73% of patients with Stage I disease and 51% of patients with Stage II/III disease. Patients who received guideline consistent care had significantly improved survival compared to those who did not. Overall, we found only moderate improvement in guideline adherence and three-year overall survival during the 13-year study time period. This study showed underutilization of stage specific guideline concordant care for stage I and II/III disease.https://www.mdpi.com/1718-7729/28/1/17gastric cancerguideline concordant caretreatment trendsNational Cancer Databasemultimodal therapycancer survival |
| spellingShingle | Kelly A. Stahl Elizabeth J. Olecki Matthew E. Dixon June S. Peng Madeline B. Torres Niraj J. Gusani Chan Shen Gastric Cancer Treatments and Survival Trends in the United States Current Oncology gastric cancer guideline concordant care treatment trends National Cancer Database multimodal therapy cancer survival |
| title | Gastric Cancer Treatments and Survival Trends in the United States |
| title_full | Gastric Cancer Treatments and Survival Trends in the United States |
| title_fullStr | Gastric Cancer Treatments and Survival Trends in the United States |
| title_full_unstemmed | Gastric Cancer Treatments and Survival Trends in the United States |
| title_short | Gastric Cancer Treatments and Survival Trends in the United States |
| title_sort | gastric cancer treatments and survival trends in the united states |
| topic | gastric cancer guideline concordant care treatment trends National Cancer Database multimodal therapy cancer survival |
| url | https://www.mdpi.com/1718-7729/28/1/17 |
| work_keys_str_mv | AT kellyastahl gastriccancertreatmentsandsurvivaltrendsintheunitedstates AT elizabethjolecki gastriccancertreatmentsandsurvivaltrendsintheunitedstates AT matthewedixon gastriccancertreatmentsandsurvivaltrendsintheunitedstates AT junespeng gastriccancertreatmentsandsurvivaltrendsintheunitedstates AT madelinebtorres gastriccancertreatmentsandsurvivaltrendsintheunitedstates AT nirajjgusani gastriccancertreatmentsandsurvivaltrendsintheunitedstates AT chanshen gastriccancertreatmentsandsurvivaltrendsintheunitedstates |